Biogen agreed to buy biotech firm Reata Pharmaceuticals for nearly $6.5 billion to bolster its position in the rare disease drugs market.
You are here: Home / Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio
Market News and Views
Biogen agreed to buy biotech firm Reata Pharmaceuticals for nearly $6.5 billion to bolster its position in the rare disease drugs market.